The maker of Tylenol is pushing back against resurfaced claims that its popular pain reliever is unsafe for pregnant women. Kenvue, the parent company of Tylenol, issued a statement Thursday after an old and now-deleted 2017 social media post resurfaced suggesting it did not recommend “any of our products while pregnant.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.

Tylenol, Kenvue’s biggest product, has been sold over-the-counter in the United States since the 1960s and makes up about 10% of group sales. Rothschild estimated that sales to expectant mothers represent less than 0.5% of Kenvue’s annual revenue.

Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.

Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.

Shares of consumer healthcare firm Kevnue dropped to a record low during regular trading Monday, then made up some ground afterhours as President Trump warned that acetaminophen, the active ingredient in Kenvue's Tylenol,

Fox rises after President Donald Trump said Lachlan and Rupert Murdoch could be part of an investor group to own TikTok.